Novel Conformationally Constrained Memapsin 2 Inhibitors for Treatment of Alzheimer's Disease

Back to all technologies
Download as PDF
65200
The processing of a precursor protein by memapsin 2 (beta-secretase, BACE 1) is the first step in the pathway leading to the production of Alzheimer's disease-causing amyloid-beta; thus, it is a major target for the development of inhibitor drugs used in the treatment of this disease.

A Purdue University researcher has designed a series of novel memapsin 2 inhibitors that incorporate conformationally constrained cyclic amine derivatives in place of conventional hydroxyethylamine isostere-derived inhibitors. These inhibitors' design improves pharmacological properties of drug forms, improving metabolic stability, oral bioavailability, and in vivo A-reductions.

Advantages:
-Improved pharmacological properties

Potential Applications:
-Medical/Health
-Pharmaceutical industry
Oct 9, 2009
Utility Patent
United States
8,703,947
Apr 22, 2014

Oct 13, 2009
Utility Patent
United States
(None)
(None)

Oct 9, 2009
PCT-Patent
WO
(None)
(None)

Oct 9, 2009
NATL-Patent
Japan
(None)
(None)

Oct 9, 2009
NATL-Patent
Canada
(None)
(None)

Oct 9, 2009
NATL-Patent
European Patent
(None)
(None)

Oct 9, 2009
NATL-Patent
India
(None)
(None)

Oct 9, 2009
PCT-Patent
WO
(None)
(None)

Oct 9, 2009
Utility Patent
United States
(None)
(None)

May 5, 2009
Provisional-Patent
United States
(None)
(None)

Mar 25, 2009
Provisional-Patent
United States
(None)
(None)

Oct 10, 2008
Provisional-Patent
United States
(None)
(None)

(None)
PCT-Patent
WO
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org